Anesthetic Effect of Ropivacaine on Local Infiltration Anesthesia in Arteriovenous Fistula Surgery
Active, not recruitingPhase 4NCT07259772
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This study compares two local anesthetics, ropivacaine and lidocaine, for patients undergoing arteriovenous fistula surgery. Arteriovenous fistula is the preferred vascular access for end-stage kidney disease patients needing hemodialysis. In this clinical trial, patients are randomly assigned to receive either ropivacaine or lidocaine for local anesthesia during the surgery. Researchers are evaluating which medication provides better pain control and improves surgical outcomes. The study is examining: * Pain levels during and after surgery * Surgery duration * Need for additional pain medication * Surgical complications * Fistula development over time * Long-term fistula function at 1 year and 5 years This is a double-blind study, meaning neither patients nor surgeons know which medication is being used. The study is currently ongoing with active patient follow-up and is expected to be completed in June 2026. Patients are being followed for up to 5 years to monitor their long-term progress. This research may help doctors choose the best local anesthetic for arteriovenous fistula surgery, potentially leading to better pain control and improved long-term outcomes for kidney disease patients.
Study details
- Official title
- Anesthetic Effect of Ropivacaine on Local Infiltration Anesthesia in Arteriovenous Fistula Surgery: a Randomized Controlled Trial
- Conditions
- End Stage Renal Disease (ESRD)
- Arteriovenous Fistula Patency
- Chronic Kidney Disease 5D
- Interventions
- Sponsor
- The First People's Hospital of Lianyungang
- Start date
- 2019-04-10
- Primary completion
- 2021-03-31
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- China
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Adult patients (aged ≥18 years) scheduled for primary radiocephalic arteriovenous fistula creation * Diagnosed with end-stage renal disease requiring hemodialysis * Willing and able to provide written informed consent Exclusion Criteria: 1. History of arteriovenous fistula on the ipsilateral limb 2. Impaired communication abilities or inability to complete questionnaires due to language barriers, or missing essential data 3. Preoperative ultrasound findings of: * Radial or brachial artery diameter \<1.8 mm * Cephalic vein diameter \<2 mm at the wrist or \<3 mm at the elbow (without tourniquet application) 4. Known allergy to local anesthetics (ropivacaine or lidocaine) 5. Coagulopathy or bleeding disorders 6. Local infection at the planned anesthesia or surgical site 7. Severe peripheral neuropathy or neurological disorders affecting upper limb function 8. Significant thrombosis or severe stenosis in the proximal major veins or central veins of the limb 9. Pregnancy or breastfeeding 10. Participation in another clinical trial within 30 days
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT07259772